Protocols›Healing & recovery›Wolverine Stack
← Protocols
Athlete / performance · huge uptake Community · the default healing stack No approved clinical use

Wolverine Stack

Stack: BPC-157 + TB-500 · the recovery / repair pairing
"Probably the most-used non-GLP-1 peptide stack on earth — the default answer to 'I'm injured.' Enormous real-world uptake. Also: animal-and-anecdote evidence, no human trials of the combination, and a regulatory status that's actively in flux. Popular is not the same as proven."
GoalTissue repair / recovery
Compounds2 · BPC-157 + TB-500
Humans exposed (est.)Very high — undocumented
StatusMHRA (UK): not a licensed medicine — research material · FDA (US): removed from restricted Category 2 (Apr 2026), under PCAC review (Jul 2026) for possible compounding — not approved, status evolving · no human trials of the combination
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Athlete / performance · huge uptake
Where / who
Bodybuilding, combat sport, general gym culture.
Developed for
Faster recovery from injury and training load.
Use status
The default healing stack — extremely widely used.
Evidence it adds
Popularity signal — not efficacy.
Basis: vast community / athlete convergence — real-world uptake, not trial data
US clinic · off-label compounding
Where / who
US functional-medicine, longevity & sports-medicine clinics — physician-prescribed via 503A/503B compounding pharmacies.
Track record
BPC-157 / TB-500: among the most commonly compounded peptides in US clinics until the Sept 2023 FDA Category 2 listing disrupted legitimate compounding — see the regulatory layer below for current status.
Evidence it adds
Real-world clinical observation — physician-charted, supervised use. A genuine evidence tier, but observational: uncontrolled, unpublished, no registry, outside formal pharmacovigilance.
What it means
Off-label compounding under prescription — never an FDA-approved therapy. Removal from Category 2 is not approval.
Basis: US compounding-pharmacy practice · FDA Docket FDA-2025-N-6895
No approved clinical use
Clinical record
No country lists BPC-157 + TB-500 as an approved therapy.
Human trials
No completed human trial of the combination; BPC-157's human efficacy data is minimal.
Basis required for a clinical-use tag: none found — absence shown, not hidden
Regulatory — status evolving
FDA (US)
Both were Category 2 (compounding prohibited) 2023–Apr 2026. Removed Apr 2026; under PCAC review (23–24 Jul 2026) for possible 503A Category 1 listing.
MHRA (UK)
Not a licensed medicine. Sold as research material.
What it means
Removal from Category 2 is not approval — the compounding decision is still pending.
Why it matters
No marketing authorisation = no pharmacovigilance; adverse events aren't formally tracked despite the huge use.
Basis: FDA Docket FDA-2025-N-6895 · PCAC meeting 23–24 Jul 2026 — this section updates after the decision
Why these two together

BPC-157 is run for local and gut repair; TB-500 for systemic cell migration and recovery. Mechanistically complementary — which is the rationale — but the rationale is preclinical. The human evidence base for the pairing does not exist yet, and that gap is the honest centre of this page.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor when stacking are part of membership. The provenance, evidence and exposure above are always free.
Start 30 days free →
No card needed · cancel anytime
Cycle shape — how it's typically structured, not a schedule to follow
Loading
~2–4 wks
Maintenance
taper down
Off
stop at recovery
Typically run around an injury, ~4–8 weeks — not continuously. Convention from community use, not a prescription.
What to watch when stacking

With no human safety profile for the combination, there is no established marker set to monitor against — which is a reason for more caution, not less. Baseline bloods and a clinician conversation matter more here, not less. General information, not medical advice.

Combination evidence
Real-world uptake Very high

Almost certainly the most-used non-GLP-1 stack. But uptake measures popularity, not effect.

Human efficacy None

Animal / mechanistic only. No human trial of the combination.

Clinical observation Observational

A decade-plus of physician-supervised, charted use — meaningful real-world signal, with no commonly-reported serious adverse-event pattern. But uncontrolled, unpublished, held in private charts (no registry) and outside formal pharmacovigilance. Not controlled evidence.

The honest ceiling

High exposure, low evidence. "Everyone uses it" and "barely studied in humans" are both true — and they sit on this page side by side.

Fast facts
Compounds

BPC-157 · TB-500

Humans exposed (est.)

Very high but undocumented — huge grey-market use, no registry. The opposite problem to the bioregulators: lots of exposure, none of it captured.

UK strip

GREEN — research material